SCHEMBL10123845

SCHEMBL10123845

CCN1CCCCC1C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP2D6 P10635 4/20 0.43
CHRM3 P20309 4/20 0.43
CHRM2 P08172 3/20 0.43
CHRM1 P11229 3/20 0.43
HRH1 P35367 3/20 0.43
KCNH2 Q12809 2/20 0.43
CHRM4 P08173 2/20 0.43
CHRM5 P08912 2/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8336619 0.95 LMNA (0.56) LMNAATML3MBTL1CYP2D6CHRM3
SCHEMBL8336623 0.95 LMNA (0.56) LMNAATML3MBTL1CYP2D6CHRM3
SCHEMBL8339280 0.95 LMNA (0.56) LMNAATML3MBTL1CYP2D6CHRM3
SCHEMBL8339348 0.84 LMNA (0.53) LMNAATML3MBTL1CHRM3CHRM2
SCHEMBL8342637 0.84 LMNA (0.53) LMNAATML3MBTL1CHRM3CHRM2
SCHEMBL8343216 0.84 LMNA (0.53) LMNAATML3MBTL1CHRM3CHRM2
SCHEMBL6207629 0.83 LMNA (0.50) LMNAATML3MBTL1CYP2D6CHRM3
SCHEMBL8481946 0.81 LMNA (0.51) LMNAATML3MBTL1CHRM3HRH1
SCHEMBL8477474 0.81 LMNA (0.51) LMNAATML3MBTL1CHRM3HRH1
SCHEMBL8477470 0.81 LMNA (0.51) LMNAATML3MBTL1CHRM3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261950-A1 Compounds that inhibit cholinesterase ACHE, BCHE, CHAT LMNA 3474/4885ATM 2695/4885L3MBTL1 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.